ArticleTranslational lung cancer research2025

Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis.

Wujian Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.